Potential Dilution from the Exercise of Stock Acquisition Rights
First written in FY2020. 5 of 8 entries say "Materialised", first in FY2021-Q2. Latest entry: FY2025.
GMO Financial Gate moved to the "Worse" side of this theme in 2021, the same year as the typical company in this theme.
The whole theme swung hardest in 2017: 28 of 54 companies on the "Worse" side.
52 other companies' latest entry also says "Mitigated".
- FY2025MitigatedAnnual report
「There were no stock options during the consolidated fiscal year.」
While dilution risk from the exercise of stock acquisition rights arose in prior fiscal years, the disclosure states that no stock options existed during the consolidated fiscal year. - FY2024-Q2MaterialisedAnnual report
「1 January 2024–31 March 2024 (Note) 34,140 8,339,480 8,747 1,638,680 8,747 1,651,791 (Note) Increase resulting from the exercise of stock acquisition rights.」
During the current second-quarter accounting period, 34,140 shares were issued through the exercise of stock acquisition rights, and capital stock and capital surplus each increased by ¥8,747 thousand. - FY2023MitigatedAnnual report
「As of 30 September 2023, the number of potential shares represented by these stock acquisition rights was 34,140 shares (0.41% of the total 8,305,340 shares issued).」
Although 45,120 shares were issued through the exercise of stock acquisition rights during the fiscal year, the number of potential shares had declined to 34,140, or 0.41% of the total shares issued, as of the end of the period. The dilution risk remains, but the unexercised portion has decreased. - FY2023-Q2MaterialisedAnnual report
「1 January 2023–31 March 2023 45,120 8,305,340 11,945 1,629,932 11,945 1,643,043 (Note) Increase resulting from the exercise of stock acquisition rights.」
The exercise of stock acquisition rights resulted in the issuance of 45,120 shares, meaning that further dilution from potential shares materialized as an actual share issuance. - FY2022-Q2MaterialisedAnnual report
「1 January 2022–31 March 2022 23,790 4,130,110 12,540 1,617,987 12,540 1,631,098 (Note) Increase resulting from the exercise of stock acquisition rights.」
The exercise of stock acquisition rights resulted in the issuance of 23,790 shares during the cumulative second-quarter period, meaning that further dilution from potential shares materialized as an actual share issuance. - FY2021MaterialisedAnnual report
「As of 30 September 2021, the number of potential shares represented by these stock acquisition rights was 63,420 shares (1.54% of the total 4,106,320 shares issued), and the policy is to continue using the stock option program.」
Although 157,950 shares were issued through the exercise of stock acquisition rights during the fiscal year, 63,420 potential shares, or 1.54%, remained as of the end of the period. - FY2021-Q2MaterialisedAnnual report
「1 January 2021–31 March 2021 Increase in total number of shares issued 110,040 (Note) Increase resulting from the exercise of stock acquisition rights.」
The exercise of stock acquisition rights resulted in the issuance of 110,040 shares, meaning that part of the dilution risk from potential shares materialized as an actual share issuance. - FY2020First statedAnnual report
「As of 30 September 2020, the number of potential shares represented by these stock acquisition rights was 221,370 shares (5.61% of the total 3,948,370 shares issued), and the policy is to continue using the stock option program.」
This indicates, together with the figure of 5.61%, the possibility that the exercise of stock acquisition rights could dilute the value of existing shareholders' shares and their voting rights.